Medication info

Empagduo Tablet 12.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
Pinkish white, biconvex, oval-shaped film-coated tablet
Packaging
60 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/PTP [10 tablets/PTP x 6]
Approval status
Active

MFDS item code 202302648 · Approved 2023.09.05

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient’s existing dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Drug Interactions in Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 1) under section 3. Caution in administration to the following patients in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see section 2) under section 2. Do not administer to the following patients in Precautions for Use). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to assist in controlling blood sugar for adult patients with type 2 diabetes who are following a dietary regimen and exercise program. It is particularly suitable for patients whose blood sugar is not adequately controlled. Patients with cardiovascular disease should refer to professional guidance and caution. This medication effectively improves blood sugar levels to help manage diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient’s existing dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Drug Interactions in Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 1) under section 3. Caution in administration to the following patients in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see section 2) under section 2. Do not administer to the following patients in Precautions for Use). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication helps to control blood sugar levels. However, there is a risk of a rare side effect called severe lactic acidosis, which can be life-threatening and therefore requires caution. Additionally, if taken in combination with insulin or sulfonylureas, there is a risk of hypoglycemia. Patients with moderate to severe renal impairment, acute kidney problems, serious infections, heart failure, acute myocardial infarction, and certain health conditions should not take this medication. It is also safest for pregnant or nursing women to avoid this medication. Before and during taking this medication, regular kidney function tests are essential, especially for the elderly or those with impaired kidney function. In situations with a risk of fluid loss, such as dehydration, severe vomiting, or diarrhea, the medication may need to be temporarily discontinued. This medication may increase the risk of urinary or genital infections, so if any infection symptoms appear, consult a healthcare professional immediately. Increased urination may occur, and symptoms of low blood pressure due to decreased fluid volume may also be present. During use, be cautious of hypoglycemia symptoms, and if taken with insulin or other blood sugar-lowering agents, dosage adjustments may be necessary to reduce the risk of hypoglycemia. This medication is not recommended for patients with liver dysfunction, and if liver damage symptoms arise, contact healthcare professionals immediately. Prior to and following exams or surgeries using iodine contrast agents, this medication should be temporarily discontinued and resumed only after the restoration of normal kidney function. Alcohol intake may increase the risk of lactic acidosis, so avoid excessive drinking during treatment. Elderly patients are at a higher risk of renal dysfunction, so dosage adjustments and regular monitoring are necessary. It is crucial to consult healthcare providers promptly if any changes in symptoms or adverse reactions occur during the course of this medication.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • decreased fluid volume
  • nausea
  • vomiting
Show 199 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • hypotension
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • ovarian-tubal abscess
  • vestibular neuritis
  • headache
  • sensory impairment
  • position-related dizziness
  • dizziness
  • drowsiness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • chills
  • strange feeling
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive urine red blood cell
  • ureteral stone disease
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary tract pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vulvovaginitis
  • cervical dysplasia
  • cervicitis
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • dyslipidemia
  • diabetes
  • hyperlipidemia
  • hyponatremia
  • vitamin D deficiency
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • pain in limbs
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival injection
  • pathological myopia
  • retinal detachment
  • retinal crystal
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery obstructive disease
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • gastric cancer
  • leiomyoma
  • pancreatic carcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • position-related vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • constipation
  • nasopharyngitis
  • herpes zoster
  • chest discomfort
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent contact with air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pinkish white, biconvex, oval-shaped film-coated tablet

Package unit

60 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/PTP [10 tablets/PTP x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.